![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Noven: FDA Nixes Delay on Generic Pain Patch
Noven: FDA Nixes Delay on Generic Pain Patch
Regulators have denied petitions to prevent or delay approval of certain generic versions of Johnson & Johnson's Duragesic, a chronic pain patch. Noven Pharmaceuticals, which disclosed the decision by the FDA, said the denied petitions were from Alza; Brookoff and Voth; London & Mead; and Steven Shafer. Miami-based Noven has applied to the FDA to market its own generic for Duragesic, a fentanyl patch.
South Florida Business Journal (http://www.bizjournals.com/southflorida/stories/2005/01/31/daily1.html)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
11Jul
-
18Jul
-
21Oct